Stocks · Healthcare · Biotechnology
Nurix Therapeutics, Inc. NRIX
$22.99 -1.50% Close, Oct 2, 2026 · NASDAQ · Market cap $2.39B
Strong trend
Next earnings report: Oct 8, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -982.4% from -260.8% a year earlier.
- The diluted share count rose 32.4% in a year.
- Over the past year the stock returned +144.6%, ahead of the S&P 500 by 129.5 percentage points.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 10%
- Revenue growth, 3-year CAGRTop 22%
- Revenue growth accelerationBottom 5%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 15%
- Gross marginBottom 5%
- Operating marginBottom 12%
- Accruals (lower is better)Top 38%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 39%
- Free-cash-flow yieldBottom 33%
- EBITDA / enterprise valueBottom 35%
- Sales / enterprise valueBottom 11%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 8%
- 6-month returnTop 20%
- 1-year return vs S&P 500Top 8%
- Distance from 52-week highTop 29%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 30%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 44%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 18%
- Maximum drawdown, 3 yearsBottom 49%
- Beta vs S&P 500 (lower is better)Bottom 42%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 27.2% | -58.4% | ↓ |
| Gross margin | -206.0% | -165.5% | ↑ |
| Operating margin | -260.8% | -982.4% | ↓ |
| FCF margin | -255.5% | -828.3% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -58.4% | 27.2% | ↓ | Bottom 10% |
| Gross margin | -165.5% | -206.0% | ↑ | Bottom 5% |
| Operating margin | -982.4% | -260.8% | ↓ | Bottom 12% |
| Net margin | -928.4% | -234.6% | ↓ | — |
| Free-cash-flow margin | -828.3% | -255.5% | ↓ | — |
| Return on invested capital | -77.3% | — | Bottom 15% | |
| Revenue growth, 3-year CAGR | 29.5% | — | Top 22% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -8.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 107.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -41.6 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -10.78%
- Shareholder yield
- -10.78%
- Share count change, 1 year
- +32.4%
- Share count change, 3-year CAGR
- +27.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through May 31, 2026 (filed Jul 9, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -9.1%
- Average 2-day reaction, last 8
- +1.0%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $34.67
- Target vs current price
- +50.8%
- Analysts with a rating
- 19
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 9, 2026 | -12.1% | +1.6% | -1.9% | +3.3% | -4.0% |
| Apr 8, 2026 | -3.9% | -4.6% | -0.3% | +1.5% | +46.6% |
| Jan 28, 2026 | +2.4% | -7.9% | -13.5% | -18.7% | -14.6% |
| Oct 9, 2025 | -22.6% | +8.8% | +3.7% | +24.8% | +75.3% |
| Jul 9, 2025 | +26.8% | +7.9% | -0.5% | -7.4% | -23.0% |
| Apr 8, 2025 | +6.9% | -4.7% | +1.3% | -0.7% | +31.0% |
| Jan 28, 2025 | -11.9% | -1.3% | -4.3% | -16.9% | -41.4% |
| Oct 11, 2024 | +0.0% | +8.1% | +13.1% | +24.6% | -13.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 9, 2026 | -$0.81 | -$0.72 | -12.1% | $9.0M |
| Apr 8, 2026 | -$0.79 | -$0.76 | -3.9% | $6.3M |
| Jan 28, 2026 | -$0.82 | -$0.84 | +2.4% | $13.6M |
| Oct 9, 2025 | -$1.03 | -$0.84 | -22.6% | $7.9M |
| Jul 9, 2025 | -$0.52 | -$0.71 | +26.8% | $44.1M |
| Apr 8, 2025 | -$0.67 | -$0.72 | +6.9% | $18.5M |
| Jan 28, 2025 | -$0.75 | -$0.67 | -11.9% | $13.3M |
| Oct 11, 2024 | -$0.67 | -$0.67 | +0.0% | $12.6M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 64.64× | — | — | Bottom 11% |
| Free-cash-flow yield | -12.76% | — | — | Bottom 33% |
| Earnings yield | -15.01% | — | — | Bottom 39% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 82
- 50-day average slope (20 days)
- +1.9%
- 200-day average slope (20 days)
- +4.0%
- Distance from 50-day average
- -9.1%
- Distance from 200-day average
- +17.4%
- RSI (14)
- 34.5
- Relative volume
- 0.53×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 36.9%
- Volatility vs own 5-year history
- 0th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.26
- Correlation with S&P 500
- 0.31
- Current drawdown from 1-year high
- -17.3%
- Maximum drawdown, 3 years
- -70.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 19, 2021 | Oct 25, 2023 | -91.5% | 697 days | Not yet recovered |
| Dec 14, 2020 | Jan 6, 2021 | -35.9% | 15 days | 8 days (Jan 19, 2021) |
| Sep 30, 2020 | Nov 9, 2020 | -34.5% | 28 days | 9 days (Nov 20, 2020) |
| Dec 8, 2020 | Dec 11, 2020 | -11.4% | 3 days | 1 days (Dec 14, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $2.39B
- EPS, diluted (TTM)
- -$3.45
- Revenue (TTM)
- $36.8M
- 52-week range
- $8.85 – $28.23
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $29.8M | $38.6M | $77.0M | $54.5M | $84.0M |
| Gross profit | -$86.7M | -$145.9M | -$112.2M | -$167.1M | $65.1M |
| Operating income | -$117.9M | -$183.9M | -$155.1M | -$213.0M | -$285.7M |
| Net income | -$117.2M | -$180.4M | -$143.9M | -$193.6M | -$264.5M |
| EPS (diluted) | -$2.73 | -$3.71 | -$2.65 | -$2.88 | -$3.05 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.6M | $13.3M | $18.5M | $44.1M | $7.9M | $13.6M | $6.3M | $9.0M |
| Net income | -$49.0M | -$58.5M | -$56.4M | -$43.5M | -$86.4M | -$78.2M | -$87.2M | -$89.5M |
| EPS (diluted) | -$0.67 | -$0.75 | -$0.67 | -$0.52 | -$1.03 | -$0.82 | -$0.79 | -$0.81 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$84.4M | -$159.8M | -$81.4M | -$172.6M | -$249.5M |
| Capital expenditure | -$5.7M | -$12.2M | -$8.4M | -$9.3M | -$14.0M |
| Free cash flow | -$90.0M | -$172.1M | -$89.8M | -$181.9M | -$263.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $150.2M | $19.4M | $3.2M | $478.5M | $238.6M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $443.5M
- Total assets
- $535.5M
- Total liabilities
- $132.9M
- Total debt
- $58.1M
- Net debt
- -$9.5M
- Shareholders’ equity
- $402.6M
As of May 31, 2026 (filed Jul 9, 2026).
Short interest
- Shares sold short
- 17,976,804
- Days to cover
- 14.05
- Change vs previous report
- +0.1%
FINRA short interest, settlement date Sep 15, 2026.